J&J Subsidiary Centocor Extends Collaboration With New Zealand's Living Cell Technologies For Encapsulation Technology
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Johnson & Johnson subsidiary Centocor has extended its two-year research collaboration with New Zealand-based Living Cell Technologies, and signed on for an exclusive two-year option to license globally LCT's encapsulation technology for human cell lines